EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieKlinische Studie (Phase III)Multizentrische StudieOpen Access

Simvastatin and Rifaximin in Decompensated Cirrhosis

Elisa Pose, César Jiménez, Giacomo Zaccherini, Daniela Campion, Salvatore Piano, Frank Erhard Uschner, Koos de Wit, Olivier Roux, Kohilan Gananandan, Wim Laleman, Cristina Solé, Sonia Alonso und 39 weitere

JAMA · 11.03.2025 · 333 (10) · 864

DOI: 10.1001/jama.2024.27441 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift JAMA, erschienen am 11.03.2025. Verfasst von Elisa Pose und 50 weiteren Autor:innen. Beteiligte Einrichtung: Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain. Hauptthemen laut MEDLINE: Hydroxymethylglutaryl-CoA Reductase Inhibitors, Liver Cirrhosis, Rifaximin, Simvastatin. Die Arbeit wurde bisher 53-mal zitiert (Crossref) und nennt 39 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NIDDK NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Importance There are no useful treatments to prevent the development of severe complications of liver cirrhosis. Simvastatin and rifaximin have shown beneficial effects in liver cirrhosis.

Objective

To assess whether simvastatin combined with rifaximin improves outcomes in patients with decompensated cirrhosis. Design, Setting, and Participants Double-blind, placebo-controlled, phase 3 trial conducted among patients with decompensated cirrhosis in 14 European hospitals between January 2019 and December 2022. The last date of follow-up was December 2022.

Interventions

Patients were randomly assigned to receive simvastatin, 20 mg/d, plus rifaximin, 1200 mg/d (n = 117), or identical-appearing placebo (n = 120) for 12 months in addition to standard therapy, stratified according to Child-Pugh class B or C. Main Outcomes and Measures The primary end point was incidence of severe complications of liver cirrhosis associated with organ failure meeting criteria for acute-on-chronic liver failure. Secondary outcomes included transplant or death and a composite end point of complications of cirrhosis (ascites, hepatic encephalopathy, variceal bleeding, acute kidney injury, and infection).

Results

Among the 237 participants randomized (Child-Pugh class B: n = 194; Child-Pugh class C: n = 43), 72% were male and the mean age was 57 years. There were no differences between the 2 groups in terms of development of acute-on-chronic liver failure (21 [17.9%] vs 17 [14.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 1.23; 95% CI, 0.65-2.34; P = .52); transplant or death (22 [18.8%] vs 29 [24.2%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.75; 95% CI, 0.43-1.32; P = .32); or development of complications of cirrhosis (50 [42.7%] vs 55 [45.8%] patients in the treatment and placebo groups, respectively; hazard ratio, 0.93; 95% CI, 0.63-1.36; P = .70). Incidence of adverse events was similar in both groups (426 vs 419; P = .59), but 3 patients in the treatment group (2.6%) developed rhabdomyolysis. Conclusions and Relevance The addition of simvastatin plus rifaximin to standard therapy does not improve outcomes in patients with decompensated liver cirrhosis. Trial Registration ClinicalTrials.gov Identifier: NCT03780673

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Hydroxymethylglutaryl-CoA Reductase InhibitorsLiver CirrhosisRifaximinSimvastatinGastrointestinal AgentsAgedFemaleHumansMaleMiddle AgedAcute-On-Chronic Liver FailureAscitesDouble-Blind MethodDrug Therapy, CombinationGastrointestinal HemorrhageHepatic EncephalopathyLiver TransplantationAcute Kidney InjuryFollow-Up StudiesIntention to Treat AnalysisTreatment OutcomeBacterial InfectionsSeverity of Illness Index

Substanzen

Hydroxymethylglutaryl-CoA Reductase InhibitorsRifaximinSimvastatinGastrointestinal Agents

Autor:innen und Institutionen

  • Liver Unit, Hospital Clínic de Barcelona, Barcelona, Spain.
  • Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain.
  • Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEReHD), Madrid, Spain.
  • Liver Unit, Hospital Universitari Vall d'Hebron, Barcelona, Spain.
  • Vall d'Hebron Institut de Recerca, Liver Unit, Universitat Autonoma de Barcelona, Department of Medicine, Barcelona, Spain.
  • Department of Medical and Surgical Sciences, University of Bologna, Bologna, Italy.

Förderung

  • NIDDK NIH HHS

Zitieren

APA

Pose, E., Jiménez, C., Zaccherini, G., Campion, D., Piano, S., Uschner, F. E., de Wit, K., Roux, O., Gananandan, K., Laleman, W., Solé, C., Alonso, S., Cuyàs, B., Ariza, X., Juanola, A., Ma, A. T., Napoleone, L., Gratacós-Ginès, J., Tonon, M., …, & LIVERHOPE Consortium (2025). Simvastatin and Rifaximin in Decompensated Cirrhosis. JAMA, 333(10), 864. https://doi.org/10.1001/jama.2024.27441

Vancouver

Pose E, Jiménez C, Zaccherini G, Campion D, Piano S, Uschner FE, et al. Simvastatin and Rifaximin in Decompensated Cirrhosis. JAMA. 2025;333(10):864. doi:10.1001/jama.2024.27441

BibTeX
@article{Pose2025,
  author = {Pose, Elisa and Jiménez, César and Zaccherini, Giacomo and Campion, Daniela and Piano, Salvatore and Uschner, Frank Erhard and de Wit, Koos and Roux, Olivier and Gananandan, Kohilan and Laleman, Wim and Solé, Cristina and Alonso, Sonia and Cuyàs, Berta and Ariza, Xavier and Juanola, Adrià and Ma, Ann T and Napoleone, Laura and Gratacós-Ginès, Jordi and Tonon, Marta and Pompili, Enrico and Sánchez-Delgado, Jordi and Allegretti, Andrew S and Morales-Ruiz, Manuel and Carol, Marta and Pérez-Guasch, Martina and Fabrellas, Núria and Pich, Judit and Martell, Claudia and Joyera, María and Domenech, Gemma and Ríos, José and Torres, Ferrán and Serra-Burriel, Miquel and Hernáez, Rubén and Solà, Elsa and Graupera, Isabel and Watson, Hugh and Soriano, Germán and Bañares, Rafael and Mookerjee, Rajeshwar P and Francoz, Claire and Beuers, Ulrich and Trebicka, Jonel and Angeli, Paolo and Alessandria, Carlo and Caraceni, Paolo and Vargas, Víctor M and Abraldes, Juan G and Kamath, Patrick S and Ginès, Pere and LIVERHOPE Consortium, LIVERHOPE Consortium},
  title = {Simvastatin and Rifaximin in Decompensated Cirrhosis},
  journal = {JAMA},
  year = {2025},
  volume = {333},
  number = {10},
  pages = {864},
  doi = {10.1001/jama.2024.27441}
}
Kostenlos starten →